Clinical Trial Search

Primary: Composite Success of Improvement in New York Heart Association (NYHA) Class and a Performance Goal for Effective Orifice Area (EOA). — 93.6; 91.7 percentage of…

Primary: Aortic Stenosis Acceleration Index Compared to Aortic Stenosis Severity — 21; 8; 1; 6 participants

Primary: Composite Score of Change in New York Heart Association (NYHA) Class and Effective Orifice Area (EOA). — 75.0; 87.5 percentage of participants analyzed — p=0.002

Primary: Percent Change in Mean Pulmonary Artery Pressure in the Whole Cohort. — -25 percent change

Primary: Procedural Success — 100 Participants

Primary: Number of Participants That Experienced One or More Components of the Composite Clinical Endpoint of MCE (Major Cardiovascular Events) — 333; 355 Participants — p=0.591

Primary: Submaximal Exercise Test — 375; 384 meters

Primary: Percent of Early Adverse Events — 1.7; 1.0; 4.5; 0.0 Percentage of subjects

Primary: FFR 6 Months After SAVR/TAVI. — -0.0279 ratio

Primary: Number of Late Adverse Events Divided by Late Patient Years (Expressed as a Percentage) for the INTUTY Valve Implanted Cohort — 3.9; 0.9; 0.6; 0.3 Percentage of…

Primary: Total Work Performed During a Maximal-effort Exercise Test

Primary: All Cause Mortality — 8 Participants

Primary: Changes in Aortic Valve Calcium Levels — 65; 215 Arbitrary Units — p=0.05

Primary: VARC-2 Composite Safety Endpoint — 12.1 percentage of patients

Primary: Extreme Risk: All-cause Death or Major Stroke; High Risk Surgical: All-cause Mortality — 26.0; 39.3; 14.1; 18.9 percentage of participants, Kaplan-Meier — p=<0.0001

Primary: Aortic Valve Mean Gradient (mm Hg) at Peak Exercise — 11; 14; 11 mm Hg

Primary: Major Adverse Cardiovascular and Cerebrovascular Events (MACCE) Rate — 0.099 probability of events at 30 days

Primary: All-cause Mortality — 4.4 Percentage of subjects

Primary: Extreme Risk: All-cause Death or Major Stroke; High Risk Surgical: All-cause Mortality — 22.5; 30.8; 17.8 percentage of participants, Kaplan-Meier

Primary: Number of Participants With All-Cause Mortality and/or Major Stroke and/or Rehospitalization — 105; 102 participants

Primary: Change From Baseline in Aortic Characteristic Impedance at Week 12 — -0.7; -2.9 dyne x sec/cm5 — p=0.7827

Primary: All-cause Mortality Rate — 1.7 percentage of participants

Primary: Percentage of Participants With All-cause Mortality — 12.1 percentage of participants

Primary: Impaired Post-operative Functional Capacity — 35 Participants

Primary: Death — 84; 89; 55; 89 participants

Primary: Number of Participants With Composite of All-cause Death, All Stroke and Aortic Insufficiency (AI) ≥ Moderate — 125 Participants

Primary: Percent of Subjects With Two-year Device-related Hemodynamic Compromise — 0.65 percentage of participants

Primary: Composite Major Adverse Event (MAE) Free Rate — 54.2; 48.1; 51.6 Percentage of subjects

Primary: Late Adverse Event Rates — 1.90; 0; 2.61; 0.12 percentage of events/late patient years

Primary: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 — 10; 43 Participants — p=<0.0001